Pliant Therapeutics Inc (PLRX)
12.19
-0.67
(-5.21%)
USD |
NASDAQ |
Apr 18, 16:00
12.24
+0.05
(+0.41%)
Pre-Market: 09:22
Pliant Therapeutics Research and Development Expense (Quarterly): 33.18M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 33.18M |
| September 30, 2023 | 32.34M |
| June 30, 2023 | 33.00M |
| March 31, 2023 | 29.27M |
| December 31, 2022 | 25.11M |
| September 30, 2022 | 24.61M |
| June 30, 2022 | 26.34M |
| March 31, 2022 | 20.88M |
| December 31, 2021 | 18.75M |
| September 30, 2021 | 21.05M |
| Date | Value |
|---|---|
| June 30, 2021 | 19.22M |
| March 31, 2021 | 18.53M |
| December 31, 2020 | 17.85M |
| September 30, 2020 | 16.88M |
| June 30, 2020 | 17.54M |
| March 31, 2020 | 13.92M |
| December 31, 2019 | 11.73M |
| September 30, 2019 | 10.78M |
| June 30, 2019 | 13.10M |
| March 31, 2019 | 11.75M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
10.78M
Minimum
Sep 2019
33.18M
Maximum
Dec 2023
21.27M
Average
19.22M
Median
Jun 2021
Research and Development Expense (Quarterly) Benchmarks
| Masimo Corp | 38.00M |
| Liquidia Corp | 12.83M |
| Vor Biopharma Inc | 20.90M |
| CEL-SCI Corp | 4.352M |
| AIM ImmunoTech Inc | 3.20M |